stockrow
Friday 6 November 2026
Export IOVA’s income statement to Excel — free account
Iovance Biotherapeutics, Inc.
IOVA Healthcare Biotechnology
Iovance Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $263.5 million, up 60.6% from fiscal 2024.
- Revenue
- +80.1%
- EPS
- +80.0%
- Free cash flow
- +89.7%
Quarter to September 2026, against a year earlier
7.99
0.25
+3.23%
Follow IOVA
Alert me
Iovance Biotherapeutics, Inc. (IOVA) Gross margin
Iovance Biotherapeutics, Inc.'s gross margin over the twelve months to 30 September 2026 was 0.00%, down 34.3 percentage points from fiscal 2025 (34.3%). That is below the Biotechnology industry median of 65.2% and below the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 34.3% | (8.89) |
| FY2024 | 43.2% | 30.05 |
| FY2023 | 13.1% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 0.00% | (56.10) |
| Jun 2026 | 56.1% | 15.60 |
| Mar 2026 | 40.5% | (9.82) |
| Dec 2025 | 50.3% | 7.36 |
| 10 more quarters | Free account |
Gross margin against peers
| Company | Gross margin |
|---|---|
| RLAY Relay Therapeutics, Inc. compare | 100.0% |
| ABCL AbCellera Biologics Inc. compare | 100.0% |
| TNGX Tango Therapeutics, Inc. compare | 100.0% |
| ACAD ACADIA Pharmaceuticals Inc. compare | 90.5% |
| XENE Xenon Pharmaceuticals Inc. compare | 28.4% |
| IOVA Iovance Biotherapeutics, Inc. | 0.00% |
| IRON Disc Medicine, Inc. compare | 0.00% |
| EWTX Edgewise Therapeutics, Inc. compare | 0.00% |
| PBLS Parabilis Medicines, Inc. compare | — |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on IOVA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement